Capricor Therapeutics

Duchenne muscular dystrophy DMD
Biotech

Capricor shares turn red as FDA announces deramiocel adcomm plan

Capricor saw its shares fall 13% as the FDA plans to hold an advisory committee to review the company's DMD hopeful.
Ben Adams May 6, 2025 8:32am
Blue race track

Capricor shares more data for DMD therapy after initiating BLA

Oct 11, 2024 11:50am
pay deal hand over cash licensing transaction money

Capricor sells Europe rights to late-stage DMD therapy for $35M

Sep 18, 2024 5:55am
traffic light green light

Capricor culls COVID-19 vax work, readies for phase 3 DMD trial

Mar 11, 2022 8:00am
handshake

Capricor, Nippon ink $705M biobucks deal for phase 3 DMD therapy

Jan 25, 2022 5:00am
Doctor working on iPad with hospital setting in background

Capricor finds efficacy in older Duchenne patients in phase 2

Sep 24, 2021 7:00am